Board and Management

Chief Scientific Officer

Professor Allison Cowin

Professor Allison Cowin is the company’s founder and Chief Scientific Officer. As Professor of Regenerative Medicine at the University of South Australia, she is internationally recognised as a leader in the field of wound healing and scar formation, and is the key innovator and inventor of AbRegen’s intellectual property portfolio. Professor Cowin has been awarded four independent research fellowships, the MS McLeod Medal for research excellence, and was nominated for an Excellence in Research2business engagement by the University of Adelaide. Her research has been included in the ’10 of the best projects’ by the Australian National Health & Medical Research Council. She holds numerous editorial and advisory board appointments including the Editorial Advisory Board of ‘Wound Repair and Regeneration’, joint editor of ‘Wound Practice and Research’, the Scientific Advisory Board of ‘The Australasian Blistering Diseases Foundation’ and is an invited member on the international expert panel for the Wound Healing and Management node of the Joanna Briggs Institute. In addition, Professor Cowin was the founder and inaugural President of the Australasian Wound & Tissue Repair Society.

Chairman

Dr Chris Goddard

Dr Chris Goddard is the Chairman of AbRegen. In addition, he is Chief Executive Officer and Managing Director of GroPep Bioreagents, an Adelaide based biotechnology company specialising in the development and manufacture of insulin-like growth factors (IGFs), IGF analogues, IGF binding proteins, polyclonal and monoclonal antibodies. Previous appointments include positions at the University of Sheffield, St. Bartholomew’s Hospital, University of London, Manchester University and the Roslin Institutue. After moving to Australia in 1994, Dr Goddard joined the start up company GroPep Pty Ltd where he built the Cell Culture business that underpinned the company’s financial success. As a member of the senior management team he was involved in the IPO of GroPep in August 2000, became an Executive Director in 2001, acting Chief Executive in 2002 and subsequently the Chief Operating Officer until the acquisition of the company by Novozymes A/S in December 2006 for ~AUD$100 million. He then moved to Novozymes’ corporate headquarters in Copenhagen to a role as Senior Director, Business Development & Acquisitions before returning to Adelaide in 2010 to re-establish GroPep Bioreagents through a management buyout.

Managing Director

Dr David Belford

Dr David Belford is the Managing Director of AbRegen. Dr Belford has over 20 years experience in scientific research and translational activities. After pursing a research career within the Commonwealth Scientific and Industrial Research Organisation and Cooperative Research Centre for Tissue Growth and Repair, where he was Leader of the Wound Healing Program, Dr Belford joined the start-up company GroPep Pty Ltd. He was a member of the senior management team that took GroPep Ltd to its successful IPO, and as Medical Director subsequently established the company’s product development capabilities, including preclinical, analytical, regulatory and clinical activities. Following the acquisition of GroPep by Novozymes A/S (for ~AUD$100M), he took a role as a Business Development Manager with the Novozymes’ Copenhagen-based Business Development and Acquisitions group before accepting the role as the foundation Director of Research for the Wound Management Innovation Cooperative Research Centre. Dr Belford holds a first class honours degree in science and a medical degree from the Flinders University of South Australia, and a PhD from the John Curtin School of Medical Research (Australian National University).

Non-Executive Board Member

Dr Stephen Rodda

Dr Stephen Rodda is a non-executive board member. Dr Rodda is the Chief Executive Officer of ITEK Ventures Pty Ltd and the Director of Research and Innovation Services at the University of South Australia. He has a combined 15 years of experience in the areas of scientific research, research management, technology commercialisation, investment management and corporate governance. Dr Rodda has been involved in technology commercialisation at every stage of the process including implementation of technology development and intellectual property strategies, capital raisings, business development and executive management of early stage companies. Throughout his career, Dr Rodda has played an active role in the formation and financing of several start-ups, securing approximately $35 million in grants and investment funding, and brings a valuable perspective on investment management from his previous role as Senior Investment Manager with a Venture Capital fund. Dr Rodda holds a first class honours degree and a PhD in Biochemistry from the University of Adelaide where he was awarded the University Medal. His post-doctoral training at Harvard University was supported by the prestigious CJ Martin and Arthritis Foundation fellowships.

IP Counsel

Dr Justin Coombs

Dr Justin Coombs provides in-house IP counsel to AbRegen. Dr Coombs is a registered patent and trade marks attorney with over 10 years’ practice experience. He has worked with two of the top patent attorney firms in Australia (Davies Collison Cave then Phillips Ormonde Fitzpatrick) where he established a substantial practice focussing on the biotechnology sector. More recently, Dr Coombs has held senior management positions in the biotechnology industry and is also the current General Manager of the Cooperative Research Centre for Cell Therapy Manufacturing. Dr Coombs obtained a Bachelor of Biotechnology with first class honours and a PhD from Flinders University in Adelaide, followed by a postdoctoral fellowship at Cornell University in the United States. Dr Coombs also holds a Masters of Intellectual Property Law from the University of Melbourne and is a Fellow of the Institute of Patent and Trade Mark Attorneys.